Kiora Pharmaceuticals (KPRX)
(Delayed Data from NSDQ)
$4.23 USD
0.00 (0.00%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $4.18 -0.05 (-1.18%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KPRX 4.23 0.00(0.00%)
Will KPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPRX
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
KPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KPRX
Kiora Pharmaceuticals Inc trading halted, news pending
12 Health Care Stocks Moving In Thursday's After-Market Session
Buy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial Data
Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024